公司对法律调查的回应 - 公司正式回应了The Schall Law Firm和DJS Law Group于2025年10月9日及10日发布的新闻稿 这些新闻稿宣布对公司涉嫌违反证券法的行为进行调查 [1] - 公司强烈反驳新闻稿中模糊且未经证实的指控 认为其缺乏事实依据或具体指控 并指出这些模糊的断言具有误导性 似乎旨在引起股东不必要的担忧 [2] - 公司认为这些公告是机会主义诉讼策略的一部分 旨在毫无依据地利用公开市场 公司正在审查相关律师事务所及其负责人的行为 并将采取一切适当行动应对其认为故意损害公司声誉的企图 [3] 公司业务与资产概况 - Quantum BioPharma Ltd 是一家生物制药公司 致力于为治疗具有挑战性的神经退行性疾病、代谢紊乱和酒精使用障碍建立创新资产和生物技术解决方案组合 其药物候选物处于不同开发阶段 [1][5] - 通过全资子公司Lucid Psycheceuticals Inc 公司专注于其主要化合物Lucid-MS的研发 该化合物是一种专利新化学实体 在临床前模型中显示可预防和逆转髓鞘降解（多发性硬化症的潜在机制） [5] - 公司发明了unbuzzd™ 并将其非处方版本分拆至Unbuzzd Wellness Inc 公司截至2025年6月30日保留Unbuzzd Wellness Inc 20.10%的所有权 并根据协议获得unbuzzd™销售额7%的特许权使用费 直至向公司的总付款达到2.5亿美元 此后特许权使用费永久降至3% 公司保留针对医药用途开发类似产品或替代配方的100%权利 [5] - 公司通过全资子公司FSD Strategic Investments Inc 持有由住宅或商业地产担保的贷款 代表其战略投资组合 [5]

诉讼背景 - 股东集体诉讼由Gross Law Firm代表在2025年4月29日至2025年8月5日期间购买Snap Inc股票的投资者提起 [1][3] - 诉讼指控公司在发布积极声明的同时 传播了重大虚假和误导性陈述 和/或隐瞒了有关Snap广告收入增长率真实状况的重大不利事实 [3] 指控核心 - 公司广告收入增长率因自身执行失败 从第一季度的9%显著下降至4月份的仅1% [3] - 公司在2025年8月5日公布第二季度财务业绩时 披露了广告收入增长减速 并将放缓归因于广告平台相关问题 斋月时间安排以及微小变化的影响 [3] 市场影响 - 负面消息公布后 Snap公司普通股股价从2025年8月5日的每股9.39美元收盘价 下跌至2025年8月6日的每股7.78美元 单日跌幅约17.15% [3]

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of V.F. Corporation (NYSE: VFC). Shareholders who purchased shares of VFC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/v-f-corporation-loss-submission-form/?id=170983&from=4 CLASS PERIOD: October 30, 2023 to May 20, 2025 ALLEGAT ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Informatica Inc. ("Informatica†or "the Company†) (NYSE: INFA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Informatica reported its Q4 2024 and full year 2024 financial results on February 13, 2025 ...

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mltx. What is this all about? Shares of MoonLake Immunotherapeutics fell more than 85% in pre-market trading on September 29 after the comp ...

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. CarMax reported disappointing financial results for Q2 2025 on September 25, 2025. The Company reported a 6.3% drop in comparable store used unit sales, and a decline in net earnings for the quarter. CarMax shares fell roughly 20% in response to its disappointing results. Accessibility StatementSkip Navigation If you are a shareholder who suffered ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169625&from=3 CLASS PERIOD: March 4, 2024 to May ...

文章核心观点 - Block & Leviton律师事务所正在调查MoonLake Immunotherapeutics公司是否存在潜在的证券法违规行为[1] 调查源于该公司披露了令人失望的三期临床试验VELA结果后 其股价在盘前交易中暴跌超过85%[2] 调查重点在于该公司此前关于药物试验的公开声明是否合规[2] 事件背景与原因 - MoonLake Immunotherapeutics股价在2025年9月29日盘前交易中下跌超过85%[2] 此次股价暴跌的直接原因是公司披露的三期VELA临床试验结果令人失望[2] 其中一项试验未能达到其主要终点 另一项试验相较于安慰剂仅显示出有限的改善[2] - 分析师认为 三期临床试验数据未能达到此前二期MIRA试验结果所设定的基准 并且落后于竞争药物 这引发了市场对该药物商业可行性的严重质疑[2] 法律调查进展 - Block & Leviton正在调查MoonLake公司关于其药物试验的公开声明 以确定其是否违反了证券法[2][4] 该律所可能代表蒙受损失的投资者提起诉讼 以尝试挽回损失[4] - 调查鼓励拥有MoonLake非公开信息的潜在举报人协助调查 或通过美国证监会的举报人计划进行报告 提供原始信息的举报人可能获得成功追回金额的最高30%作为奖励[6] 公司及行业影响 - MoonLake Immunotherapeutics是一家在纳斯达克上市的生物技术公司 专注于免疫疗法领域[1] 其核心产品三期临床试验的失败 对公司的研发前景和药物商业化潜力造成了重大打击[2] - 临床试验数据不及预期且落后于竞争对手 反映出公司在特定治疗领域的研发可能面临严峻挑战 并影响了市场对该公司及其所属细分行业的信心[2]

Accessibility StatementSkip Navigation NEWTOWN, Pa., Sept. 15, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Synopsys, Inc. ("Synopsys") (NASDAQ: SNPS), resulting from allegations of providing potentially misleading business information to the investing public. If you have information that could assist in the Synopsys investigation, or if you are a Synopsys investor who suffered a loss and would like to learn more, you can provide ...

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Block & Leviton LLP is investigating Barnes & Noble Education, Inc. (NYSE: BNED) for potential securities law violations. Investors who have lost money in their Barnes & Noble investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bned. What is this all about? Shares of Barnes & Noble stock price fell more than 20% on July 21, 2025, after the company disclosed delays in fili ...